211 related articles for article (PubMed ID: 12678734)
1. Novel concepts in the development of platinum antitumor drugs.
Fuertes MA; Castilla J; Alonso C; Pérez JM
Curr Med Chem Anticancer Agents; 2002 Jul; 2(4):539-51. PubMed ID: 12678734
[TBL] [Abstract][Full Text] [Related]
2. New platinum antitumor complexes.
Kelland LR
Crit Rev Oncol Hematol; 1993 Dec; 15(3):191-219. PubMed ID: 8142057
[TBL] [Abstract][Full Text] [Related]
3. [Drug discovery research in in-vivo antitumor-active azolato-bridged dinuclear Pt(II) complexes].
Komeda S
Yakugaku Zasshi; 2012; 132(3):253-9. PubMed ID: 22382827
[TBL] [Abstract][Full Text] [Related]
4. Fresh platinum complexes with promising antitumor activity.
Wang X
Anticancer Agents Med Chem; 2010 Jun; 10(5):396-411. PubMed ID: 20545618
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
[TBL] [Abstract][Full Text] [Related]
6. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
[TBL] [Abstract][Full Text] [Related]
7. Novel approaches towards development of non-classical platinum-based antineoplastic agents: design of platinum complexes characterized by an alternative DNA-binding pattern and/or tumor-targeted cytotoxicity.
Momekov G; Bakalova A; Karaivanova M
Curr Med Chem; 2005; 12(19):2177-91. PubMed ID: 16178779
[TBL] [Abstract][Full Text] [Related]
8. Platinum complexes as anticancer agents.
Kostova I
Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):1-22. PubMed ID: 18221023
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, cytotoxic activity and DNA interaction studies of new dinuclear platinum(ii) complexes with an aromatic 1,5-naphthyridine bridging ligand: DNA binding mode of polynuclear platinum(ii) complexes in relation to the complex structure.
Konovalov B; Živković MD; Milovanović JZ; Djordjević DB; Arsenijević AN; Vasić IR; Janjić GV; Franich A; Manojlović D; Skrivanj S; Milovanović MZ; Djuran MI; Rajković S
Dalton Trans; 2018 Oct; 47(42):15091-15102. PubMed ID: 30303498
[TBL] [Abstract][Full Text] [Related]
10. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473).
Holford J; Raynaud F; Murrer BA; Grimaldi K; Hartley JA; Abrams M; Kelland LR
Anticancer Drug Des; 1998 Jan; 13(1):1-18. PubMed ID: 9474239
[TBL] [Abstract][Full Text] [Related]
11. Recent Developments in the Field of Anticancer Platinum Complexes.
Galanski MS
Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):285-95. PubMed ID: 18221042
[TBL] [Abstract][Full Text] [Related]
12. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
13. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair.
Brabec V
Prog Nucleic Acid Res Mol Biol; 2002; 71():1-68. PubMed ID: 12102553
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of two novel anionic and cationic platinum complexes in the treatment of osteosarcoma.
Igarashi K; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Odani A; Tsuchiya H
Anticancer Agents Med Chem; 2015; 15(3):390-9. PubMed ID: 25511510
[TBL] [Abstract][Full Text] [Related]
15. Current status of the development of trans-platinum antitumor drugs.
Pérez JM; Fuertes MA; Alonso C; Navarro-Ranninger C
Crit Rev Oncol Hematol; 2000 Aug; 35(2):109-20. PubMed ID: 10936468
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic and biological characteristics of different sugar conjugated 2-methyl malonatoplatinum(II) complexes as new tumor targeting agents.
Gao X; Liu S; Shi Y; Huang Z; Mi Y; Mi Q; Yang J; Gao Q
Eur J Med Chem; 2017 Jan; 125():372-384. PubMed ID: 27688191
[TBL] [Abstract][Full Text] [Related]
18. Multi-nuclear platinum drugs: a new paradigm in chemotherapy.
Wheate NJ; Collins JG
Curr Med Chem Anticancer Agents; 2005 May; 5(3):267-79. PubMed ID: 15992354
[TBL] [Abstract][Full Text] [Related]
19. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex.
Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V
Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biological evaluation and SAR studies of novel bicyclic antitumor platinum(IV) complexes.
Lorenzo J; Delgado A; Montaña ÁM; Mesas JM; Alegre MT; Rodríguez Mdel C; Avilés FX
Eur J Med Chem; 2014 Aug; 83():374-88. PubMed ID: 24980119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
